A team led by Department of Veterans Affairs (VA) researchers recently identified three genetic mutations that govern cholesterol levels, which could lead to the development of new drugs to treat cardiovascular disease and diabetes. Detailed results of the study can be found in the Oct. 1 issue of Nature Genetics, a scientific journal. Using data from VA's Million Veteran Program (MVP), the researchers found that three genes (PDE3B, PCSK9 and ANGPTL4) could be targets for treatment of heart disease, abdominal aortic aneurysm and diabetes, respectively. To learn more about VA research, including MVP, visit the VA Office of Research and Development website.
For more on veteran benefits, visit the Military.com Benefits section.